Trial · NCT03753113

Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%

NCT03753113, Phase 3, Completed, Farid Masoud; results first posted 2020-03-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%. Trials, record NCT03753113. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03753113

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
NCT number: NCT03753113
Status: Completed
Phases: Phase 3
Enrollment: 24 participants, actual
Lead sponsor: Farid Masoud
Conditions: Androgenetic Alopecia
Interventions: Topical Herbal Solution, Topical Minoxidil 5%
First posted: 2018-11-26
Last updated: 2020-03-16
Results first posted: 2020-03-16
Limitations and caveats: Small numbers of subjects

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Hair Diameter	baseline, 12, 24, and 36 weeks	Change in hair diameter over time as compared to Baseline. Hair diameter measured via a digital micrometer.
Secondary	Patients Self - Assessment Questionnaire	through study completion	Self-administered hair growth questionnaire, consisting of 4 questions in the patient's language on treatment efficacy and three questions on satisfaction with appearance. For differences between self-assessment questionnaires. This questionnaire following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. Higher scores indicated a worse outcome.
Secondary	Adverse Events	baseline, 12, 24, and 36 weeks	Incidence of adverse events such as itching, redness, inflammation etc

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Hair Diameter	baseline, 12, 24, and 36 weeks		micrometer	MEAN
SECONDARY	Patients Self - Assessment Questionnaire	through study completion	All participants for whom data were collected at weeks 36.	score on a scale	MEAN
SECONDARY	Adverse Events	baseline, 12, 24, and 36 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Hair Diameter	Treatment Group	Week 12	57.42	Standard Deviation 8.88	micrometer
Change in Hair Diameter	Control Group	Week 12	51.58	Standard Deviation 7.67	micrometer
Change in Hair Diameter	Treatment Group	Week 24	60.92	Standard Deviation 7.35	micrometer
Change in Hair Diameter	Control Group	Week 24	51.17	Standard Deviation 7.82	micrometer
Change in Hair Diameter	Treatment Group	Week 36	62.67	Standard Deviation 7.19	micrometer
Change in Hair Diameter	Control Group	Week 36	50.58	Standard Deviation 7.38	micrometer
Patients Self - Assessment Questionnaire	Treatment Group		1.25	Standard Deviation 0.452	score on a scale
Patients Self - Assessment Questionnaire	Control Group		2.58	Standard Deviation 0.669	score on a scale
Adverse Events	Treatment Group	scalp itching	1		Participants
Adverse Events	Control Group	scalp itching	4		Participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment Group	12
Overall Study	STARTED	Control Group	12
Overall Study	COMPLETED	Treatment Group	12
Overall Study	COMPLETED	Control Group	12
Overall Study	NOT COMPLETED	Treatment Group	0
Overall Study	NOT COMPLETED	Control Group	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	scalp itching	Skin and subcutaneous tissue disorders	Treatment Group	1	12
other	scalp itching	Skin and subcutaneous tissue disorders	Control Group	4	12
other	scalp dryness	Skin and subcutaneous tissue disorders	Treatment Group	0	12
other	scalp dryness	Skin and subcutaneous tissue disorders	Control Group	2	12
other	headache	Nervous system disorders	Treatment Group	0	12
other	headache	Nervous system disorders	Control Group	2	12
serious	Blurred vision	Eye disorders	Treatment Group	0	12
serious	Blurred vision	Eye disorders	Control Group	0	12
serious	Chest pain	Musculoskeletal and connective tissue disorders	Treatment Group	0	12
serious	Chest pain	Musculoskeletal and connective tissue disorders	Control Group	0	12

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment Group	0	12
Total, all-cause mortality	Control Group	0	12
Total, other adverse events	Treatment Group	1	12
Total, other adverse events	Control Group	8	12
Total, serious adverse events	Treatment Group	0	12
Total, serious adverse events	Control Group	0	12

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33112463	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Treatment Group vs Control Group: deaths from any cause	Trial comparisons
Treatment Group vs Control Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03753113

GET https://conductscience.org/api/trials/v1/NCT03753113/registered

API reference For AI assistants